Piramal Pharma's Impressive Score in 2025 S&P Global CSA
Piramal Pharma Limited (PPL) has achieved a remarkable score of 63 on the 2025 S&P Global Corporate Sustainability Assessment (CSA). This is a significant milestone, representing a 15% improvement from last year’s score of 55. Such accomplishments illustrate PPL's ongoing dedication to sustainable practices and responsible operational strategies.
Understanding the S&P Global CSA Evaluation
The S&P Global CSA stands as a highly regarded annual test that examines the sustainability initiatives of numerous companies globally. With its rigorous criteria, the CSA evaluates organizations based on their environmental, social, and governance (ESG) performance. This assessment serves as one of the most extensive benchmarking tools available, aiding companies in aligning their sustainability goals with industry standards.
Why Sustainability Matters
A strong performance on the CSA not only provides validation of a company’s efforts but also builds trust with consumers and stakeholders. Higher scores can enhance an organization’s profile among global investors, demonstrating a commitment to sustainable growth and ethical practices. Piramal's position in the 91st percentile within the pharmaceutical sector is a testament to its effective sustainability strategy.
Key Contributors to PPL's Success
PPL's success can be attributed to its well-defined four-pillared sustainability framework. This approach incorporates Business Resilience, Quality & Excellence, Responsible Operations, and Stakeholder Centricity as core principles of operations. By focusing on these critical areas, PPL ensures compliance and enhances its responsible operational ethos.
Leadership Insights
Peter DeYoung, the CEO of Piramal Global Pharma, expressed pride in the company's progress on the S&P Global CSA. He highlighted that this achievement reaffirms their commitment to responsible practices. As PPL continues to expand globally, they strive for excellence, which not only benefits their business but also fosters a healthier global community.
The Path to Greater Sustainability
Given the insights gained from this assessment, PPL stands ready to take further steps in enhancing its sustainability measures. The company recognizes the importance of acting as a catalyst for positive change, leveraging its resources and knowledge to support environmental and social improvements.
About Piramal Pharma Limited
Piramal Pharma Limited (PPL) operates with a robust portfolio that includes diverse products and services across 17 global development and manufacturing facilities. Catering to over 100 countries, PPL integrates various aspects of the pharmaceutical landscape, including Piramal Pharma Solutions (PPS), which functions as an esteemed contract development and manufacturing organization (CDMO). Also featured is Piramal Critical Care (PCC), reflecting their involvement in complex hospital generics. Additionally, PPL oversees its Consumer Healthcare segment, focused on wellness innovations in the market.
Strategic Collaborations and Investments
One of PPL's notable joint ventures is with Abbvie Global, creating Abbvie Therapeutics India Private Limited, which is recognized as a market leader in the ophthalmology sector within India. Furthermore, PPL is strategically invested in Yapan Bio Private Limited, bolstering its position in the biologics and vaccine domains.
Frequently Asked Questions
What score did Piramal Pharma achieve in the 2025 S&P Global CSA?
Piramal Pharma achieved a score of 63, indicating a 15% improvement from the previous year.
What is the significance of the S&P Global CSA?
The S&P Global CSA evaluates sustainability practices within companies and serves as a benchmark for corporate sustainability performance.
Which pillars support Piramal Pharma's sustainability strategy?
The sustainability strategy is built on four pillars: Business Resilience, Quality & Excellence, Responsible Operations, and Stakeholder Centricity.
Who is the CEO of Piramal Pharma?
Peter DeYoung is the CEO of Piramal Global Pharma.
In which industries does Piramal Pharma operate?
Piramal Pharma operates within the pharmaceutical industry and includes segments such as contract manufacturing, critical care, and consumer healthcare.
